Before synthetic corticosteroids came about, treatment options for inflammation and autoimmune disorders stayed limited. Researchers found ways to transform simple steroids into complex, highly effective medicines. Dexamethasone's discovery, in the late 1950s, changed how doctors manage conditions like asthma, severe allergies, and certain cancers. The creation of intermediates in its chemical synthesis opened the door for cost-effective manufacturing. These intermediates, including key ketone and halogenated compounds, formed the building blocks for what now serves in countless hospital pharmacies. As industrial chemists refined the route, waste decreased, yield improved, and the environmental footprint shrank. The industry pushed research toward greener methods, like catalytic hydrogenation and enzymatic steps, moving away from more hazardous reagents. The progress of dexamethasone intermediates reflects decades of collaboration between academic researchers and pharmaceutical manufacturers, bridging discovery and widespread patient access.
Dexamethasone intermediates stand as the crucial links in the chain to the finished drug. In my work with chemical suppliers, I’ve seen how these intermediates drive the timeline of medicine production. These aren’t flashy finished drugs, but bulk chemicals, appearing as off-white powders or crystalline solids, moving swiftly through quality checks before entering reactors destined for the next synthesis step. Companies rely on their consistent purity, documented origin, and traceability, because a slip early in production ripples through to a failed batch or, worse, a medicine shortage. Without the right benchmarked intermediates, the supply of affordable dexamethasone dries up, especially for generic manufacturers in lower-income countries.
Most dexamethasone intermediates take a solid form at room temperature, with defined melting points, densities near 1 g/cm³, and good stability under anhydrous conditions. These properties allow long-term storage and bulk transport—critical for scaling up pharmaceutical manufacturing. They tend to dissolve in ethanol, chloroform, or acetone, but show poor solubility in water, which plays a role in their chemical handling and formulation design. Chemically, they display characteristic reactivity of their steroid skeletons: sensitive to acids, prone to rearrangement under strong base, and able to accept or donate halogens or hydroxyl groups. Each intermediate presents a unique challenge, as even small changes create major shifts in pharmacological activity and legal status.
Specifications run deep for these products. Reliable producers provide details on assay (usually exceeding 98% by HPLC), limit tests for heavy metals, residual solvents drawn from ICH Q3C guidelines, plus defined optical rotation—crucial for confirming stereochemistry in steroid molecules. Labeling covers more than just the chemical name and batch: manufacturers print expiry dates, recommended storage (dry, below 25°C), and universal hazard warnings. Reliable labeling ensures compliance with domestic and international regulations, crucial when intermediates cross borders for final drug formulation.
The most common preparation involves the oxidation and halogenation of simpler steroidal compounds, often using chemical routes that start from naturally sourced diosgenin or sitosterol. Labs activate specific carbon atoms with hydrobromic acid or acetic anhydride, followed by selective reduction, keeping the process efficient and minimizing waste wherever possible. The whole sequence requires strict temperature and humidity control. Engineers use glass-lined reactors and invest in continuous flow methods, which cut cycle times and improve worker safety, when compared to traditional batch chemistry. Almost every step needs real-time monitoring to guard against side-reactions and off-specification product, because impurities stick around and complicate purification in later steps.
Each chemical modification in the intermediate changes the drug’s final profile. Introduction of a 9α-fluoro or 16α-methyl group, for example, cranks up anti-inflammatory power while dialing down unwanted mineralocorticoid effects. These reactions call for fine-tuned reagents like fluorinating agents or methylcopper complexes. Other steps fine-tune the molecule with oxidation, acetylation, or ketone protection. Experienced chemists—many learning the hard way—track byproducts through NMR and mass spec, knowing even trace contamination matters for later patient safety.
Dexamethasone intermediates travel under many names through global markets, depending upon their exact structure and use. Names like 16α-methylprednisolone, 9α-fluoro-androstenedione, or simply "Intermediate C" show up in trade catalogs and regulatory paperwork. In one contract lab, I watched teams cross-check synonyms in chemical inventory systems because confusion can lead not only to regulatory trouble, but to failed synthesis or, in rare cases, accidents with incompatible materials.
Strict standards keep the field safe. In my own experience, handling these powders means full PPE: gloves, splash-proof goggles, sometimes even air filtration. Even trace skin exposure or inhalation brings risk, because these chemicals act on hormone pathways. GHS pictograms and warning statements leave no room for error, flagging reproductive toxicity or environmental persistence. Companies train new workers through hands-on drills; oversight agencies like OSHA and national equivalents lay out audits, inspections, and contingency plans for spills or fire. Waste streams, often contaminated with halogens or solvents, call for specialized disposal and local authority oversight.
Dexamethasone intermediates live mostly in bulk pharmaceutical manufacturing, but their reach spreads beyond that. Applied in the production of anti-inflammatory, immunosuppressive, and anti-allergic drugs, these compounds move through supply chains to reach every continent. Generic drug producers depend on reliable sourcing to keep costs low and supplies steady, especially in settings with tight healthcare budgets. Some research outfits investigate new structural derivatives, aiming for longer-acting or tissue-targeted therapies.
In one academic project, researchers worked on catalytic, metal-free routes to these intermediates, hoping for lower energy inputs and less hazardous waste. Companies invest in process analytics—like near-infrared spectroscopy—for real-time monitoring, so they spot off-standard batches quickly. A push exists for continuous manufacturing, using automated microreactors that promise tighter control, safer working conditions, and less raw material lost in each cycle. These R&D efforts won’t solve every problem, but they keep the process from stagnating, bridging the gap between laboratory curiosity and mass-market reliability.
Researchers at major public health institutions run toxicity assays on dexamethasone intermediates, studying their mutagenic, teratogenic, and environmental properties. Many studies involve rodent models and cell-based screens, looking for hormone disruption or organ toxicity. Regulations require full toxicity profiles not just for the finished drug, but for key process intermediates, especially if small quantities may appear in final products. Labs monitor effluent streams for bioaccumulation risks and pursue greener alternatives where warranted.
Future directions revolve around safer, greener routes, tighter supply chain integration, and preparation methods tailored for leaner manufacturing. Digital supply chain tracking will soon let buyers trace intermediates back to their source, reducing the risk of counterfeiting. Look for more partnerships between academic chemists and large-scale manufacturers, chasing new catalysts or biocatalytic routes that use less energy and generate less waste. As healthcare systems push to expand access to essential medicines, efficient and trustworthy production of dexamethasone intermediates will stay central, keeping costs down and reliability high.
Factories and laboratories often introduce dexamethasone intermediate as a crucial step in the journey from raw chemicals to finished medications. Years spent in the healthcare field have shown me how these building blocks affect not only the efficiency of pharma supply chains but also patients’ lives on a day-to-day basis. This intermediate doesn’t sit on pharmacy shelves, but without it, patients battling inflammatory conditions, autoimmune disorders, or allergies would have fewer reliable treatment options.
Pharmaceutical firms rely on dexamethasone intermediate to create the finished active pharmaceutical ingredient found in asthma inhalers, eye drops, and tablets prescribed for arthritis or severe allergies. Dexamethasone itself has earned a reputation as an effective corticosteroid, especially since studies highlighted its role saving critically ill COVID-19 patients. Without high-quality intermediates along the production line, medicine shelves across hospitals and clinics look a lot emptier.
From speaking with pharmacists over the years, I’ve learned how much frustration low drug stock causes for both staff and patients. Small disruptions at the level of intermediates spark much bigger problems downstream. Shipments delayed by even a week can turn routine flare-up management or post-surgery care into serious health risks. That’s why clean, reliable production and transport of intermediates like this one are not just technical issues; they’re health issues affecting thousands who depend on these drugs every day.
Familiar brands and generic manufacturers invest heavily in sourcing dexamethasone intermediates, especially from suppliers who prove their own compliance with safety and quality. The World Health Organization emphasizes how dexamethasone plays a part in essential medicine lists, reflecting its impact on global health. Shortages in the raw product show up as gaps in hospitals far from where intermediates get manufactured.
Poor oversight or inconsistent quality standards result in wasted batches and failed inspections. I’ve seen pharmaceutical partners spend millions on rigorous analysis and on-site audits before agreeing to contract with a supplier. Transparent supply lines, clear certificates of analysis, and third-party testing lower the risks to patients and cut costs caused by delayed or failed batches.
Lab managers, pharmacists, and purchasing teams express the same wish: a more robust, monitored production process. Quality assurance teams at each step can spot errors before shipments leave the warehouse. Robust traceability helps buyers make informed decisions. The best suppliers maintain open communications with regulators and provide evidence at every checkpoint.
International standards continue to improve. Laboratories now rely on digital batch records to catch failures early. This shift comes from a real need—one lab misstep endangers the finished medicine a doctor hands to a patient struggling to breathe. Encouraging more hands-on collaboration between manufacturers, governments, and front-line clinicians will get safe, effective medications into the hands of people who need them most.
Dexamethasone intermediate isn’t just another chemical tossed in a bin. It’s a building block in the journey to create a corticosteroid that plays a role in managing inflammation and immune responses. Anyone working around this powder knows that temperature, humidity, and exposure to light affect its stability and purity. Overlooking storage basics means risking a major setback: lost product and wasted investment.
Most pharmaceutical labs rely on room temperature control for chemicals like dexamethasone intermediates, aiming for 20°C to 25°C (68°F to 77°F). If temperatures climb too high, even for a few days, degradation can sneak in. Researchers once shared stories of batches gone bad during unseasonal heatwaves—what was supposed to last months changed color and failed quality tests. Keeping things in a cool, dry area isn’t just for comfort. It’s about protecting the integrity of the substance.
Moisture poses a real risk in pharmaceutical storage. Dexamethasone intermediates often come in tightly sealed containers because humidity encourages hydrolysis and other unwanted reactions. One rainy season taught a hard lesson: careless handling and cracked seals led to clumpy, useless powder, leaving a lasting imprint on production timelines. Every minute spent checking seals and monitoring storage conditions pays off by protecting the batch’s value.
Direct sunlight changes more than temperature in a storeroom. Chemical structure can shift under ultraviolet rays. Imagine a storeroom with a skylight—it probably sounded like a creative idea to some architect, but for pharmaceuticals it’s a disaster waiting to happen. Opaque or amber containers block light and protect valuable contents. Little details—like keeping cartons out of sunlight—show respect for the science and money invested in each shipment.
Contamination isn’t always obvious. Shared storage spaces write a recipe for cross-contamination between active ingredients and intermediates. Pharmaceutical guidelines stress separation, for good reason. Scraps of another drug or small dust particles can compromise purity and fail audits. Storage should stay organized, clean, and free from unrelated chemicals.
No policy or equipment can replace training and day-to-day vigilance. Every member of a team must understand the value behind each rule. People who take shortcuts put the entire supply chain at risk—regulators don’t take kindly to excuses about lost batches. Well-trained professionals recognize issues quickly, label batches clearly, and fix storage slips before they spiral into bigger problems. Regular audits and a culture of shared responsibility build habits that save both money and lives.
Storage conditions for dexamethasone intermediates aren’t trivial housekeeping. They determine success in later manufacturing steps and the safety of the final medicine. Reliable air conditioning, dehumidifiers, and light-proof cartons cost money up front, but investing now avoids the massive waste of failed products. Modern monitoring tools track both temperature and humidity, sending alerts if something drifts out of range. Simple habits—like double-checking lids and storing away from vents—matter as much as expensive equipment.
Those who respect the demands of dexamethasone intermediate storage lay the groundwork for quality. No one forgets the long days spent salvaging botched batches. A little planning and steady vigilance spare everyone from repeating hard lessons, and patients waiting for the medicine get the quality they deserve.
Dexamethasone sits in hospital pharmacies and research labs as a critical steroid for tackling inflammation and managing different medical conditions. Long before it enters a vial or tablet, though, a series of chemical steps bring us a compound called a dexamethasone intermediate. Chemists working with steroids know these intermediates as building blocks—a handful of carbon, hydrogen, and oxygen atoms arranged in a carefully crafted backbone. In the world of synthetic corticosteroids, these chemical precursors usually keep the steroid structure mostly complete, but tweak a group here or there to guide the reaction toward the final active ingredient.
Dexamethasone itself carries the formula C22H29FO5. Its intermediates often fall close to this mark, with minor differences—an extra functional group attached to the skeleton, an alcohol group swapped for a ketone, or a fluorine atom waiting to be placed. Most laboratories recognize names like 16α-Methyl-9α-fluoro-11β,17α-dihydroxyandrost-1,4-diene-3,20-dione when talking about precursors.
Why does that arrangement matter so much? A single misplaced oxygen or a missing methyl group can make a huge difference: the intermediate can end up biologically inactive or chemical transformations can stall. Even in university labs, I’ve seen students run into trouble by mixing up compounds—costly, since steroids don’t come cheap or easy.
A lot of folks underestimate the headaches caused by impurities during production. Something as simple as too much residual solvent or a leftover precursor from earlier in the synthesis can trigger regulatory red flags. For dexamethasone intermediates, each batch needs to hit strict standards for residual solvents, heavy metals, and by-products. Pharmacopeias spell out acceptable limits, and high-performance liquid chromatography (HPLC) gets used frequently to check for rogue particles in every lot.
The medical community cares because a single contaminated batch of intermediate can lead to faulty dexamethasone, and ultimately impact patients whose health rests on those molecules. Pharmacists and doctors count on robust, repeatable chemistry, not uncertainty in the chain of manufacturing.
The biggest lesson from the world of intermediates? There’s no substitute for tight quality control and deep chemical understanding. When I worked alongside chemists in a pharmaceutical company, daily discussions revolved around process improvements: How can we minimize waste? How do we verify that this batch holds just the right arrangement of atoms? Better training helps new staff spot inconsistencies and understand why one impurity matters more than another.
Producers who clearly label intermediates with molecular structure, batch history, and impurity thresholds raise the bar for safety. Transparent supply chains help downstream buyers trust what’s arriving on their loading docks. Automation and digital recordkeeping make tracking batches easier. Supervisors who teach the chemistry behind each production step see fewer costly errors and more motivated teams. Laboratories that invest in regular instrument calibration catch minor issues before they snowball into major supply hiccups.
As new versions of dexamethasone get developed, careful attention to every intermediate becomes part of earning pharmacy and regulatory approval. Laboratories, regulators, and drug makers together build a system where every gram of precursor meets expectations, turning a granular understanding of chemical composition into safer medicine for real people. Every link in the chain—quality managers, chemists, vendors—shares the weight of that responsibility.
I’ve spent years navigating the world of pharmaceuticals. Dexamethasone’s name comes up all the time, especially since the pandemic made this corticosteroid a household term. But behind every finished tablet sits an entire process of chemical building blocks. Dexamethasone intermediates are just that—unfinished pieces. Folks unfamiliar with the chemistry might assume that if the end drug can be lifesaving, any component along the way should be safe as well. That’s not the case.
Pharmaceutical creation runs through multiple steps. Each link in the chain produces something chemical engineers call an “intermediate”—it’s not the drug yet. These intermediates might share some structure or function with the finished medicine, but they haven’t been refined or tested the way the final product has. Safety testing for intermediates isn’t as strict. Regulators like the FDA and EMA focus their strictest regulations on the finished medicines that will reach patients. The raw and unfinished nature of intermediates means unknown impurities, unpredictable reactions in the body, and often, higher toxicity than the final drug.
Anyone who’s worked a lab bench knows: You don’t handle raw intermediates without gloves, goggles, or even a mask. Some of these chemicals might only cause minor irritation, but others can leave burns, trigger allergic reactions, or break down into more harmful substances. Dexamethasone intermediates weren’t made for dedicated use in people. Industry rules classify them closer to raw materials or precursors. They sometimes contain byproducts that would never be allowed in finished drugs—the kind of contaminants that could quietly slip past even experienced eyes if the right processes aren’t followed. These byproducts might bring out short-term symptoms or even trigger long-term disease if someone is exposed repeatedly.
Finished dexamethasone tablets, sprays, and injections go through piles of research before any doctor can hand them to a patient. Pharmaceutical companies run expensive studies, regulators demand meticulous records and multiple trials, and safety checks become relentless. No one expects intermediates to pass these same checkpoints. That’s the heart of the issue. Taking an intermediate skips all the science that proves a final drug is helpful, not harmful. There’s also no guarantee of dose or purity, so nobody can predict how the body will react—or how dangerous the outcome might be.
The answer isn’t about asking if an intermediate is safe, but challenging why anyone would want to take it. Marketing or selling intermediates for human consumption runs into deep legal and ethical trouble. If an intermediate makes it to an ingredient list, there’s a system failure somewhere—a broken supply chain, a rogue batch, or mislabeling. Solving this takes sharp vigilance from all sides: advanced tracking systems, chemicals sourced only from reputable manufacturers, and law enforcement ready to investigate and prosecute wrongdoing.
Knowing exactly what goes into every pill helps prevent mistakes. Traceability, strict testing, and clear communication between chemical manufacturers, pharmaceutical companies, and regulators make a difference. If a shortcut or counterfeit batch escapes detection, it needs to be caught before it reaches the public. Patients and health professionals must understand that only fully tested, approved formulations belong in the medicine cabinet. Intermediates are essential for research and production—but they have no place near patient care. If questions come up about what’s in a drug, direct answers and open access to manufacturing data offer the strongest way to build trust. Earning that trust keeps everyone safer in the end.
Packaging is not just about holding a product; it shapes how a material like Dexamethasone Intermediate moves from manufacturer to user. Every choice in this process speaks to safety, stability, compliance, and practicality. In my time consulting for pharma supply chains, I’ve seen how one misstep in the packaging phase can ripple through the entire operation, risking value, safety, and even regulatory approval.
Drums, both high-density polyethylene (HDPE) and steel, take the lead for large quantities. They can hold anywhere from 25 kg to 200 kg or more. HDPE resists most chemicals, moisture, and impact, which helps avoid leaks or spoilage. If the batch will sit in storage or face rough transit, steel drums bring extra toughness. These containers often carry UN certification, so they pass the scrutiny of both shipping authorities and regulatory agencies.
Too many times, I’ve seen folks cut corners with containers, and the cost comes back multiplied. HDPE drums suit most cases, but temperature swings or a rough supply chain can call for the durability of steel. In bulk, the right drum can be the difference between a successful batch and a recall.
Inside the drums, double-layered polyethylene bags or liners add another level of protection. Some companies go with aluminum foil liners if moisture control matters. Dexamethasone Intermediate, like plenty of other pharmaceutical building blocks, doesn’t mix well with water or air. Liners seal out these threats. It may sound small, but from experience, one wrong liner in a rainy season can spoil an entire lot.
If the client needs smaller volumes or easier handling, laminated kraft paper sacks and food-grade plastic bags come into play. These usually range from 5 kg up to 25 kg. They’re geared toward laboratories or companies testing new formulations that don’t need a full drum. The trade-off is that sacks rarely provide the same barrier protection as hard drums—so the material spends less time on a shelf.
I’ve seen some companies use vacuum-sealed bags when every gram matters, especially for export or sensitive storage. The science says limiting oxygen and humidity can stretch shelf life and cut contamination risks. It takes extra gear and handling, but for a high-value intermediate, the payoff speaks for itself.
Customers and authorities both turn up the heat on sustainability. Some suppliers now offer recycled plastics or drums that break down faster in landfills. Compostable liners attract attention, though their use in pharma draws extra scrutiny. I’ve worked with packaging teams weighing these alternatives; they want to cut waste but also tick every safety box. Balancing these priorities calls for open communication between buyers, regulators, and suppliers.
Ultimately, choosing how to package Dexamethasone Intermediate relies on understanding the supply path, storage risks, and purpose of use. Regulations set boundaries, but so do practical concerns like climate, freight conditions, and user needs. The best packaging safeguards both the product and the end customer—the only way to keep trust and business thriving in the pharma world.
| Names | |
| Preferred IUPAC name | (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one |
| Other names |
9α-Fluoro-16α-methylprednisolone
Dexamethasone base Fluormethylprednisolone |
| Pronunciation | /ˌdɛk.səˈmɛθ.ə.səʊn ˌɪn.təˈmiː.di.ət/ |
| Preferred IUPAC name | (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one |
| Other names |
9α-Fluoro-16α-methylprednisolone
Dexamethasone Base Hexadecadrol Maxidex Ozurdex |
| Pronunciation | /ˌdɛk.səˈmɛθ.ə.səʊn ˌɪn.təˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 446-72-0 |
| Beilstein Reference | 1503654 |
| ChEBI | CHEBI:41879 |
| ChEMBL | CHEMBL1201097 |
| ChemSpider | 20894329 |
| DrugBank | DB01234 |
| ECHA InfoCard | 07db8f02-78be-4c7e-8847-9db6ab3503fb |
| EC Number | 211-295-6 |
| Gmelin Reference | 473366 |
| KEGG | C01942 |
| MeSH | Dexamethasone |
| PubChem CID | 10607 |
| RTECS number | HA8050000 |
| UNII | 6PG8G3A41I |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID5051941 |
| CAS Number | 14484-47-0 |
| 3D model (JSmol) | `load =C23H31FO5` |
| Beilstein Reference | 1914740 |
| ChEBI | CHEBI:41879 |
| ChEMBL | CHEMBL1203 |
| ChemSpider | 1476 |
| DrugBank | DB01234 |
| ECHA InfoCard | ECHA InfoCard: 100.047.750 |
| EC Number | 237-468-3 |
| Gmelin Reference | 87844 |
| KEGG | C00021 |
| MeSH | Dexamethasone Intermediate MeSH: D004283 |
| PubChem CID | 5743 |
| RTECS number | MI8050000 |
| UNII | JCJ4M017G0 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID4046863 |
| Properties | |
| Chemical formula | C22H29FO5 |
| Molar mass | 392.46 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.32 g/cm³ |
| Solubility in water | Insoluble |
| log P | 1.83 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 12.45 |
| Basicity (pKb) | 12.48 |
| Magnetic susceptibility (χ) | -9.2e-6 |
| Refractive index (nD) | 1.546 |
| Dipole moment | 2.45 D |
| Chemical formula | C22H29FO5 |
| Molar mass | 392.46 g/mol |
| Appearance | White or light yellow crystalline powder |
| Odor | Odorless |
| Density | 1.32 g/cm3 |
| Solubility in water | slightly soluble |
| log P | 1.83 |
| Acidity (pKa) | 12.45 |
| Basicity (pKb) | 12.11 |
| Magnetic susceptibility (χ) | -9.2e-6 |
| Refractive index (nD) | 1.5700 |
| Viscosity | Viscous liquid |
| Dipole moment | 5.69 D |
| Pharmacology | |
| ATC code | H02AB02 |
| ATC code | H02AB02 |
| Hazards | |
| Main hazards | Suspected of causing cancer. Causes damage to organs through prolonged or repeated exposure. Causes serious eye damage. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P273, P280, P301+P312, P305+P351+P338, P330, P337+P313, P501 |
| Flash point | 94.8°C |
| LD50 (median dose) | LD50 (median dose): Mouse (oral) 500 mg/kg |
| NIOSH | RA3850000 |
| PEL (Permissible) | PEL (Permissible) for Dexamethasone Intermediate: Not established |
| REL (Recommended) | 0.2 mg/kg |
| IDLH (Immediate danger) | Not established |
| Main hazards | Suspected of causing cancer. Causes damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P273, P280, P301+P312, P305+P351+P338, P308+P313 |
| Flash point | Flash point >110°C |
| LD50 (median dose) | LD50 (median dose): Mouse (oral) 16 mg/kg |
| NIOSH | SW3697000 |
| PEL (Permissible) | 15 mg/m3 |
| REL (Recommended) | 6-16 mg/day |
| Related compounds | |
| Related compounds |
9α-Fluoro-16α-methylprednisolone
Prednisolone Betamethasone Hydrocortisone Triamcinolone Methylprednisolone |
| Related compounds |
Prednisone
Prednisolone Hydrocortisone Betamethasone Triamcinolone Methylprednisolone |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 395.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -135.2 kJ/mol |
Providing high-quality chemical products and logistics solutions for global trade partners.
